Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 128052

Sort by

Sort Order Select

Journal Articles

Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010

Simon Harrison, Phoebe Joy Ho, Sueh-Li Lim, Stephanie Talam, Hannah Pahl, Dharmesh Dingar, Scott Currence, Travis Quigley, Andrew Spencer

Blood (2025) 146 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2025-LBA-1

Published: 2025

Journal Articles

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Blood (2025) 146 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2025-LBA-2

Published: 2025

Journal Articles

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Blood (2025) 146 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2025-LBA-3

Published: 2025

Journal Articles

Whole genome transcriptome sequencing in inherited bone marrow failure syndromes and related diseases – the ibmdx study

Blood (2025) 146 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2025-LBA-4

Published: 2025

Journal Articles

A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The traction trial

Blood (2025) 146 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2025-LBA-5

Published: 2025

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Sinto Chirackal, Gregory Ahmann, Esteban Braggio, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2025-2139

Published: 2025

Journal Articles

Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes

Yusuke Yamashita, Jonathan Patton, Yuliza Shotts, Megan Du, Meaghen Sharik, Kirsten Pfeffer, Yuan Zhu, Chang-Xin Shi, Caleb Stein, Erin Meermeier, Marta Chesi, Lanbo Xiao, Arul Chinnaiyan, Benjamin Barwick, P. Leif Bergsagel

Blood (2025) 146 (Supplement 1): 2138.

https://doi.org/10.1182/blood-2025-2138

Published: 2025

Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Blood (2025) 146 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2025-2137

Published: 2025

Journal Articles

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Jennifer Huang, Laura Samples, Ted Gooley, Margo Fredericks, Stephanie Louie, Grace Bishop, Christine Crider, Mehrdad Azar, Neena Kennedy, Mengyang Di, Stephen Smith, Brian Till, Ajay Gopal, Ryan Lynch, Chaitra Ujjani, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2025-2136

Published: 2025

Journal Articles

Impact of prior venetoclax use on mortality in CLL patients treated with pirtobrutinib: A propensity-matched cohort study

Kanishka Uttam Chandani, Ritu C. Tated, Sarah Monick, Pragyat Futela, Dhruvi Joshi, Sooraj Srirangadhamu Gopu, Jatin Thukral, Diana Zamora Quintanilla, Apoorva Kondapally, Talal Hilal

Blood (2025) 146 (Supplement 1): 2135.

https://doi.org/10.1182/blood-2025-2135

Published: 2025

Journal Articles

A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL

Georgios Pongas, Matthew Mei, Lu Chen, Geoffrey Shouse, Rachel Bellsmith, Ivana Melgar, Steven Rosen, Tanya Siddiqi, Alexey Danilov

Blood (2025) 146 (Supplement 1): 2134.

https://doi.org/10.1182/blood-2025-2134

Published: 2025

Journal Articles

Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 2133.

https://doi.org/10.1182/blood-2025-2133

Published: 2025

Journal Articles

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

Yun Wang, Chunhua Li, Robert Gale, Qi Liang, Neil Kay, Victoria Wang, Qianqian Huang, Yiling Song, Weida Wang, Yang Liang

Blood (2025) 146 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2025-2132

Published: 2025

Journal Articles

Initial treatment of chronic lymphocytic leukemia with low-dose high-frequency rituximab followed by addition of acalabrutinib

Charles Chu, Clare Heffernan, Nydia Jaimes-Delgadillo, Christine Herne, Jennifer Bruno, Andrea Baran, Paul Barr, Ronald Taylor, John Ashton, Michael Elliott, Clive Zent

Blood (2025) 146 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2025-2131

Published: 2025

Journal Articles

Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders

Sean McKeague, Thomas Lew, LeiShong Lau, Philip Thompson, Ashley Whitechurch, Dennis Carney, Gemma Reynolds, Piers Blombery, John Seymour, Andrew Roberts, Mary Ann Anderson

Blood (2025) 146 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2025-2130

Published: 2025

Journal Articles

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Constantine Tam, Talha Munir, Tadeusz Robak, Jennifer Brown, Brad Kahl, Paolo Ghia, Stephen Opat, Patricia Walker, Masa Lasica, Ian Flinn, Jiayi Shen, Nataliya Kuptsova-Clarkson, Marcus Lefebure, Jamie Hirata, Wojciech Jurczak, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2025-2129

Published: 2025

Journal Articles

Ibrutinib plus rituximab leads to superior progression-free and overall survival to FCR in previously untreated CLL: Results of the Phase III NCRI FLAIR trial

Blood (2025) 146 (Supplement 1): 2128.

https://doi.org/10.1182/blood-2025-2128

Published: 2025

Journal Articles

Orelabrutinib combined with short-course bendamustine-rituximab (BR) for first-line treatment of chronic lymphocytic leukemia: A prospective multicenter study

Linlin Cao, Hao Song, Guolin Wu, Hu Mao Gui, Qiang Xu, CuiCui Wang, Dandan Fan, Yuanyuan Feng, ChenYang Zhou, Jing Ming, Xinchen Wang, Jing Wang, Meiqi Ding, Youzhi Wu, Long Zhong, Kaiyang Ding

Blood (2025) 146 (Supplement 1): 2127.

https://doi.org/10.1182/blood-2025-2127

Published: 2025

Journal Articles

Impact of autoimmune hemolytic anemia on prognosis in chronic lymphocytic leukemia patients: A comprehensive retrospective analysis

Liang Wang, Yuting Yan, Lugui Qiu, Tingyu Wang, Shuhua Yi

Blood (2025) 146 (Supplement 1): 2126.

https://doi.org/10.1182/blood-2025-2126

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Whole genome transcriptome sequencing in inherited bone marrow failure syndromes and related diseases – the ibmdx study

A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The traction trial

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Impact of prior venetoclax use on mortality in CLL patients treated with pirtobrutinib: A propensity-matched cohort study

A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL

Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

Initial treatment of chronic lymphocytic leukemia with low-dose high-frequency rituximab followed by addition of acalabrutinib

Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Ibrutinib plus rituximab leads to superior progression-free and overall survival to FCR in previously untreated CLL: Results of the Phase III NCRI FLAIR trial

Orelabrutinib combined with short-course bendamustine-rituximab (BR) for first-line treatment of chronic lymphocytic leukemia: A prospective multicenter study

Impact of autoimmune hemolytic anemia on prognosis in chronic lymphocytic leukemia patients: A comprehensive retrospective analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only